SecBot SecBot

ADAG

Adagene Inc.
Nasdaq· Pharmaceutical Preparations· Inc. E9· CIK 0001818838 Biotech & Drug Discovery
$2.41 −0.03 (−1.23%)
Oct 23 4:00 PM ET · prev $2.44
Market cap
$161.2M
Micro cap
Consensus
Buy
92% Buy or better · 12 analysts
Median target
🔒 Subscribers only
1 year
+34.6%
from $1.79 · Oct 24
30 days
−19.1%
from $2.98
52-week range
$1.40–4.78
−50% from high · low Nov 7
Avg volume 20D
381.9K
Oct 9 spike 1.65M
Short interest
2.11M
≈3.2% of shares · +0.6%
Days to cover
7.5
at average volume
Insider net
+$162.2K
3 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
12
analyzed by SecBot
SecBot read BULLISH 7 reports · 90 days
Balance 0 bearish · 2 bullish · 1 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 2/7
Strongest BULLISH Adagene received NMPA clearance to begin a Phase 1 trial of ADG138, a double-masked HER2xCD3 bispecific…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    3 insiders bought $162.2K at an average $3.41. No open-market sales. Price is 29% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 6 added (0 new), 2 trimmed or exited.

  • AnalystsBULLISH

    11 of 12 rate it Buy or better.

  • Short sellersSTEADY

    Short interest +0.6% to 2.11M shares. 7.5 days to cover, ≈3.2% of shares.

  • TrendDOWNTREND

    24% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
AMERIPRISE FINANCIAL INCDOUBLED1,716,711$7.2M
RENAISSANCE TECHNOLOGIES LLCDOUBLED146,500$615.3K
UBS Group AGDOUBLED124,063$521.1K
Quadrature Capital LtdDOUBLED80,487$338.0K
GEODE CAPITAL MANAGEMENT, LLCADD17,994$75.6K
MORGAN STANLEYNEAR_EXIT7,961$33.4K
BNP PARIBAS FINANCIAL MARKETSDOUBLED7,900$33.2K
JPMORGAN CHASE & COTRIM452$1.9K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 92% rate it Buy or better
Strong Buy4Buy7Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 19, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 14, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 10, 2026Chardan Capital
INITIATE
INITIATEBuy

Insider ledger

Form 4
$162.2K
bought · 3 insiders
$0
sold · 0 insiders
−29.4%
vs their $3.41 cost
DateInsiderTypeValue
Sep 23, 2026
Tam Man Kin
Chief Financial Officer
BUY$6.0K
Sep 16, 2026
Luo Peter
Chief Executive Officer
BUY$64.0K
Aug 14, 2026
DO CUONG V
Director
BUY$7.5K
Aug 13, 2026
Grawunder Ulf
Director
AWARD20,000 sh
Aug 13, 2026
Zhu Li
Director
AWARD20,000 sh
Aug 13, 2026
DO CUONG V
Director
AWARD20,000 sh
Aug 13, 2026
Cheung Andy Yiu Leung
Director
AWARD20,000 sh
Aug 5, 2026
Luo Peter
Chief Executive Officer
BUY$1.0K

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
2,114,139
shares short
+0.6%
vs prior settlement
7.5
days to cover
≈3.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 25, 2026 SEC
Adagene Inc. filed a 6-K reporting the resignation of Ms. Chunfang (Vicky) Gu as Executive Director of Finance…
6-K — Impact 2/10
Sep 23, 2026 Insider
Tam Man Kin bought 2,000 shares
Chief Financial Officer @ $3.00 ($6.0K)
Sep 22, 2026 SEC
Adagene received NMPA clearance to begin a Phase 1 trial of ADG138, a double-masked HER2xCD3 bispecific T-cell…
6-K — Impact 5/10
Sep 16, 2026 Insider
Luo Peter bought 20,290 shares
Chief Executive Officer @ $3.15 ($64.0K)
Sep 10, 2026 SEC
Adagene announced that its partner Third Arc Bio selected the first lead candidate under their amended strategic…
6-K — Impact 5/10
Aug 14, 2026 Insider
DO CUONG V bought 2,000 shares
Director @ $3.75 ($7.5K)
Aug 12, 2026 Earnings
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results
Jun 30, 2026 Inst.
AMERIPRISE FINANCIAL INC — DOUBLED
1,716,711 shares ($7.2M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Aug 12, 2026
Earnings
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration…
Aug 10, 2026
Earnings date
ADAG Q2 2026 Earnings Scheduled — 2026-08-10
Jun 15, 2026
Short interest
Short Interest: ADAG up 45% to 1.9M shares
Settlement 2026-06-15 | Days to cover: 12.11 | ≈2.81% of shares outstanding (est.)
May 12, 2026
Press release
Adagene to Participate in Two Upcoming Investor Conferences
SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the…
Apr 17, 2026
Press release
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab +…

SecBot reports

12 filings · 4 press releases · 4 bullish · 1 bearish · 1 mixed · 6 neutral
All ADAG filing & press-release reports (16)